Systems and methods for characterizing kidney disease

Abstract

The present invention relates to methods of diagnosing, predicting and monitoring kidney disorders. In particular, the present invention relates to the diagnosis, prediction and monitoring of kidney disorders by detection of cytokines, cytokine-related compounds and chemokines in urine. The present invention further relates to methods and compositions for assessing the efficacy of agents and interventions used to treat kidney disorders.

1 - 24 . (canceled) 
   
   
       25 . A method of detecting disorders of the kidney, comprising:
 a) providing;
 i) a urine sample from a subject, wherein said subject is suspected of having a kidney disorder; and 
 ii) reagents for detection of Mig; and 
   b) detecting the amount of said Mig in said urine sample using said reagents to detect said disorders of the kidney, wherein said amount of said compound in said urine sample is at least 20 pg/ml.   
   
   
       26 . The method of claim  1 , wherein said amount of said compound in said urine sample is at least 60 pg/ml. 
   
   
       27 . The method of claim  1 , wherein said amount of said compound in said urine sample is at least 100 pg/ml. 
   
   
       28 . The method of claim  1 , wherein said reagents comprise reagents for performing an immunoassay. 
   
   
       29 . The method of  claim 28 , wherein said immunoassay is selected from the group consisting of an ELISA, radio-immunoassay, automated immunoassay, cytometric bead assay, and immunoprecipitation assay. 
   
   
       30 . The method of claim  1 , further comprising the step of determining a treatment course of action based on said diagnosis of a kidney disorder. 
   
   
       31 . The method of claim  1 , further comprising the step of determining the presence or absence of a concurrent infection in said subject. 
   
   
       32 . The method of claim  1 , further comprising detecting the amount of IP-10 in said urine sample. 
   
   
       33 . The method of claim  1 , further comprising detecting the amount of osteoprotogerin in said urine sample. 
   
   
       34 . The method of claim  1 , further comprising detecting the amount of MIP-1δ in said urine sample.